Evotec secures $2.9 million Gates Foundation grant for drug safety testing
EVO•Evotec secured a $2.9 million Gates Foundation grant to extend early drug safety testing for three years. The project uses human stem cells to assess potential fetal development risks from drug candidates.
1. Grant extends testing
Evotec secured a $2.9 million Gates Foundation grant to extend early drug safety testing for three years. Launched in 2023, the project uses human stem cells to assess potential fetal development risks from drug candidates.




